Recent Analysts’ Ratings Changes for Immunocore (IMCR)

Several analysts have recently updated their ratings and price targets for Immunocore (NASDAQ: IMCR):

• 5/9/2026 – Immunocore was upgraded by Wall Street Zen from “hold” to “buy”.
• 5/7/2026 – Immunocore was upgraded by Zacks Research from “strong sell” to “strong-buy”.
• 4/27/2026 – Immunocore was downgraded by Zacks Research from “hold” to “strong sell”.
• 4/21/2026 – Immunocore had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 4/20/2026 – Immunocore had its “buy” rating reaffirmed by HC Wainwright. They now have a $100.00 price target on the stock.
• 4/14/2026 – Immunocore had its “buy” rating reaffirmed by HC Wainwright. They now have a $100.00 price target on the stock.
• 3/16/2026 – Immunocore was downgraded by Jefferies Financial Group Inc. from “buy” to “hold”. They now have a $33.00 price target on the stock, down from $48.00.

Insider Buying and Selling

In related news, insider Leger Tina Amber St sold 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $32.35, for a total value of $32,350.00. Following the sale, the insider owned 1,119 shares in the company, valued at $36,199.65. This represents a 47.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Bahija Jallal sold 11,474 shares of Immunocore stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $32.35, for a total value of $371,183.90. Following the transaction, the chief executive officer owned 12,343 shares of the company’s stock, valued at $399,296.05. The trade was a 48.18% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 19,137 shares of company stock worth $619,082 in the last 90 days. Insiders own 10.40% of the company’s stock.

Immunocore plc is a clinical?stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T?cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T?cell receptors against cancer) platform utilizes engineered, soluble T?cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease?associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma?associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.